Investors propelled Synthomer’s stock sharply higher on Friday, with the specialty chemicals group seeing an advance of approximately 9.5% by midday. The market rally was a direct response to the company’s clarified approach to strengthening its balance sheet, which explicitly rules out an equity raise that would dilute existing shareholders.
Strategic Focus: Cost Cuts and Divestments
The firm’s strategy now emphasizes rigorous internal cost-saving initiatives and the divestiture of non-core business segments. This plan to repair its financial position without issuing new shares was a key driver behind the significant trading interest. Friday’s trading volume was notably high, running about 40% above the daily average.
2025 Guidance Confirmed Amid Demand Challenges
Synthomer reaffirmed its full-year 2025 expectations. Management anticipates sales of around £1.74 billion, with adjusted EBITDA projected to land between £135 million and £138 million. The company attributed its ability to maintain stable margins in the face of softer market demand to disciplined cost-reduction programs and enhanced operational execution.
Should investors sell immediately? Or is it worth buying Synthomer?
Refinancing Efforts Underway
A major point of reassurance for the market was the confirmation that a capital increase is not currently on the agenda. To address its debt, Synthomer is pursuing a structured divestment program and is actively negotiating new credit terms. Discussions are ongoing with lenders to extend the maturity dates for its revolving credit facilities and UK Export Finance funding, which are currently set to mature in the second half of 2027.
Operational Stability and Forward Look
Despite geopolitical tensions in the Middle East, the company reported normal operations at its local joint ventures and sales offices. Looking ahead, the primary focus for the current year remains on driving profitability through self-help efficiency gains. Preparations for the publication of the detailed annual report at the end of April 2026 are proceeding according to schedule.
Ad
Synthomer Stock: Buy or Sell?! New Synthomer Analysis from March 30 delivers the answer:
The latest Synthomer figures speak for themselves: Urgent action needed for Synthomer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 30.
Synthomer: Buy or sell? Read more here...
